Evaluation of BRCA1/2 mutation status among women with triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text ...
GOLDEN, Colo., Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (THER) (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast ...
Predicting cancer dependencies from molecular data can help stratify patients and identify novel therapeutic targets. Recently available data on large-scale cancer cell line dependency allow a ...
Protein microarrays are one aspect of highly automated, large-scale biological screening technologies, the other is nucleic acid arrays. As DNA arrays reveal their origin in Southern blotting ...
Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase ...
RICHMOND, VIRGINIA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- The Virginia Innovation Partnership Corporation (VIPC) today announced that George Mason ...
Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding from Georgiamune, Inc., for a project in which Georgiamune, Inc., will provide cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results